Publication: UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells
Issued Date
2020-09-01
Resource Type
ISSN
14320584
09395555
09395555
Other identifier(s)
2-s2.0-85086850355
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Hematology. Vol.99, No.9 (2020), 2027-2036
Suggested Citation
Tiwaporn Nualkaew, Pinyaphat Khamphikham, Phitchapa Pongpaksupasin, Woratree Kaewsakulthong, Duantida Songdej, Kittiphong Paiboonsukwong, Orapan Sripichai, James Douglas Engel, Suradej Hongeng, Suthat Fucharoen, Natee Jearawiriyapaisarn UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells. Annals of Hematology. Vol.99, No.9 (2020), 2027-2036. doi:10.1007/s00277-020-04136-w Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58023
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
UNC0638 induces high levels of fetal hemoglobin expression in β-thalassemia/HbE erythroid progenitor cells
Abstract
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Increased expression of fetal hemoglobin (HbF) improves the clinical severity of β-thalassemia patients. EHMT1/2 histone methyltransferases are epigenetic modifying enzymes that are responsible for catalyzing addition of the repressive histone mark H3K9me2 at silenced genes, including the γ-globin genes. UNC0638, a chemical inhibitor of EHMT1/2, has been shown to induce HbF expression in human erythroid progenitor cell cultures. Here, we report the HbF-inducing activity of UNC0638 in erythroid progenitor cells from β-thalassemia/HbE patients. UNC0638 treatment led to significant increases in γ-globin mRNA, HbF expression, and HbF-containing cells in the absence of significant cytotoxicity. Moreover, UNC0638 showed additive effects on HbF induction in combination with the immunomodulatory drug pomalidomide and the DNMT1 inhibitor decitabine. These studies provide a scientific proof of concept that a small molecule targeting EHMT1/2 epigenetic enzymes, used alone or in combination with pomalidomide or decitabine, is a potential therapeutic approach for HbF induction. Further development of structural analogs of UNC0638 with similar biological effects but improved pharmacokinetic properties may lead to promising therapies and possible clinical application for the treatment of β-thalassemia.